Atopic Dermatitis MCQ Quiz | Allergic Dermatoses

1. Mutations in which gene are most strongly associated with an impaired skin barrier function in Atopic Dermatitis?

2. The inflammatory process in Atopic Dermatitis is predominantly driven by which type of T-helper cell response?

3. According to the Hanifin and Rajka diagnostic criteria, which of the following is considered a MAJOR criterion for Atopic Dermatitis?

4. In the infantile phase of Atopic Dermatitis, which body area is most characteristically affected?

5. The presence of an extra fold of skin beneath the lower eyelid in patients with Atopic Dermatitis is known as:

6. What is the most common organism responsible for secondary bacterial infections (impetiginization) in Atopic Dermatitis?

7. Eczema herpeticum, a potentially life-threatening complication of Atopic Dermatitis, is caused by a widespread infection with which virus?

8. Which of the following is considered the cornerstone and first-line therapy for all severities of Atopic Dermatitis?

9. A common transient side effect reported with the initial use of topical calcineurin inhibitors like tacrolimus and pimecrolimus is:

10. Dupilumab, a biologic agent for moderate-to-severe Atopic Dermatitis, works by targeting the receptor for which key cytokines?

11. Which of the following is a MINOR criterion for the diagnosis of Atopic Dermatitis?

12. The “headlight sign” in infantile atopic dermatitis refers to the characteristic sparing of which facial area?

13. Chronic, repeated scratching in Atopic Dermatitis leads to skin thickening and accentuation of skin markings, a process known as:

14. An infant presents with a greasy, scaly rash on the scalp (“cradle cap”) and in the skin folds, with less prominent itching. Which condition is the most important differential diagnosis for Atopic Dermatitis?

15. Crisaborole is a non-steroidal topical treatment for Atopic Dermatitis that functions by inhibiting which enzyme?

16. Hertoghe’s sign, often seen in patients with chronic Atopic Dermatitis, refers to:

17. Which symptom is universally present and is a hallmark of Atopic Dermatitis, often described as “the itch that rashes”?

18. For severe, recalcitrant Atopic Dermatitis unresponsive to topical therapy and phototherapy, which systemic agent is a well-established conventional immunosuppressant?

19. The primary therapeutic goal of using emollients in Atopic Dermatitis is to:

20. The “Atopic March” refers to the typical progression of atopic diseases, which usually begins with Atopic Dermatitis in infancy and is often followed by the development of:

21. Serum levels of which immunoglobulin are frequently, though not universally, elevated in patients with Atopic Dermatitis?

22. Upadacitinib and Abrocitinib are newer oral medications for Atopic Dermatitis that belong to which class of drugs?

23. When prescribing a topical calcineurin inhibitor like tacrolimus, patients should be counseled about the importance of:

24. The “itch-scratch cycle” is a key concept in the pathophysiology of Atopic Dermatitis because it directly perpetuates:

25. Which form of phototherapy is most commonly and effectively used for treating chronic, widespread Atopic Dermatitis?